Title : Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism.

Pub. Date : 2002 Oct

PMID : 12364422






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism. Raloxifene Hydrochloride gonadotropin releasing hormone 1 Homo sapiens
2 This prospective randomized, single-blind, placebo-controlled clinical trial was performed to evaluate the efficacy of raloxifene in preventing the bone loss associated with GnRH agonist (GnRH-a) administration. Raloxifene Hydrochloride gonadotropin releasing hormone 1 Homo sapiens
3 This prospective randomized, single-blind, placebo-controlled clinical trial was performed to evaluate the efficacy of raloxifene in preventing the bone loss associated with GnRH agonist (GnRH-a) administration. Raloxifene Hydrochloride gonadotropin releasing hormone 1 Homo sapiens
4 In conclusion, raloxifene prevents GnRH-a related bone loss in premenopausal women with uterine leiomyomas. Raloxifene Hydrochloride gonadotropin releasing hormone 1 Homo sapiens